174 related articles for article (PubMed ID: 36058752)
1. Evolving management of early stage pancreatic adenocarcinoma in older patients.
Nassoiy S; Christopher W; Marcus R; Keller J; Weiss J; Chang SC; Essner R; Foshag L; Fischer T; Goldfarb M
Am J Surg; 2023 Jan; 225(1):212-219. PubMed ID: 36058752
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Neoadjuvant Therapy and Upfront Resection for Patients with Resectable Pancreatic Adenocarcinoma: An Instrumental Variable Analysis.
da Costa WL; Tran Cao HS; Sheetz KH; Gu X; Norton EC; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3186-3195. PubMed ID: 33174146
[TBL] [Abstract][Full Text] [Related]
4. Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer - an analysis of the Swedish national pancreatic cancer registry.
Sternby H; Andersson B
Scand J Gastroenterol; 2022 Nov; 57(11):1361-1366. PubMed ID: 35635264
[TBL] [Abstract][Full Text] [Related]
5. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
6. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
Ivey GD; Shoucair S; Delitto DJ; Habib JR; Kinny-Köster B; Shubert CR; Lafaro KJ; Cameron JL; Burns WR; Burkhart RA; Thompson EL; Narang A; Zheng L; Wolfgang CL; He J
World J Surg; 2022 Nov; 46(11):2751-2759. PubMed ID: 35861852
[TBL] [Abstract][Full Text] [Related]
8. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
Rieser CJ; Zenati M; Narayanan S; Bahary N; Lee KK; Paniccia A; Bartlett DL; Zureikat AH
Ann Surg Oncol; 2021 Oct; 28(11):6264-6272. PubMed ID: 33748894
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
[TBL] [Abstract][Full Text] [Related]
10. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
11. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma.
Zhu L; Shen S; Wang H; Zhang G; Yin X; Shi X; Gao S; Han J; Ren Y; Wang J; Jiang H; Guo S; Jin G
BMC Cancer; 2023 Aug; 23(1):790. PubMed ID: 37612635
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
[TBL] [Abstract][Full Text] [Related]
13. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
14. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
[TBL] [Abstract][Full Text] [Related]
15. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
17. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
18. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
